Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 May 2018 Photo Charl Devenish
Open Day an exciting event for prospective Kovsies
Faculties gave students a taste of what studying at UFS is like.

Grade 12 learners and their parents and teachers from all over the Free State and outside the province were at the Bloemfontein Campus on 12 May 2018, to explore what the University of the Free State (UFS) has to offer. Faculties and departments all came together to give the visitors a great experience and a glimpse of what they can expect as first years in 2019. 

Exhibitions showcase excellence in education

“I plan to study for an accounting degree and I am excited because I’ve already got my sights on UFS,” said Oratile Segapo from Taung in North West. Oratile had visited the Faculty of Economic and Management Sciences, which like other faculties, held exhibitions on course information with teaching aids, models, and much more, demonstrating the high calibre of teaching and learning facilities at UFS, as well as innovation and technology-based education. At the Faculty of Law learners had the opportunity to interact with academics and the dean, and to listen to motivational talks by senior students, and former SRC members.

One of the highlights of Open Day is that learners can apply online to study at UFS. More than 150 learners were assisted in applying at the Van der Merwe Scholtz Hall. Other departments such as Student Recruitment Services, the UFS Library and the office of International Affairs were present to engage with learners and their parents.
 
Campus community coming together
The Rector and Vice-Chancellor Prof Francis Petersen had a session with learners and parents, giving them an opportunity to learn more about his vision for the university and to discuss their interest in the university.

The offices of Student Affairs, Community Engagement, Health and Wellness and Protection Services also gave learners a feel of what student life would be like as well as the support they could receive once becoming Kovsies.

“The Open Day was very well organised, and my daughter, who is doing Grade 11, is definitely planning on studying here once she matriculates. We were impressed with the activities and the ability to engage so easily with programme coordinators,” said Wilmarie du Toit.

The UFS Open Day is an annual event that is hosted at the Bloemfontein and Qwaqwa Campuses, and attracts hundreds of learners to experience Kovsies for themselves. The Qwaqwa Campus Open Day will be held on 26 May 2018.

2018 Bloemfontein Campus Open Day highlights from University of the Free State on Vimeo.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept